Kezar Life Sciences' zetomipzomib drug for lupus nephritis has been placed on clinical hold by the FDA following serious safety concerns. The company continues its autoimmune hepatitis trials while reallocating resources from other programs. read more
Read Also
- Amazon is selling an 'exceptional' $345 knife set for only $135, and shoppers say it's 'a cut above the rest'
- Review: The Store, Oxford – purveyors of excellence
- David Rosenberg: Housing numbers signal Bank of Canada is still way behind the curve
- Govt to pump around $11 billion for construction of new and expand existing airports: Civil Aviation Minister
- Meat exporters to follow QCI certification for Halal meat from Oct 16
- Trump Considers Robinhood Exec Dan Gallagher For SEC Chair If Re-Elected
- 12 Consumer Discretionary Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Industrials Stocks Moving In Monday's Intraday Session
- 12 Information Technology Stocks Moving In Monday's Intraday Session
Latest Benzinga
- Trump Considers Robinhood Exec Dan Gallagher For SEC Chair If Re-Elected
- 12 Consumer Discretionary Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Industrials Stocks Moving In Monday's Intraday Session
- 12 Information Technology Stocks Moving In Monday's Intraday Session
- Peering Into Modine Manufacturing's Recent Short Interest
- Peering Into Ally Financial's Recent Short Interest
- Here's How Much You Would Have Made Owning AerCap Holdings Stock In The Last 15 Years
- Peering Into ATI's Recent Short Interest
- Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year